A commentary on the use of pharmacoenhancers in the pharmaceutical industry and the implication for DMPK drug discovery strategies.

Martins, Vanessa; Fazal, Lynsey; Oganesian, Aram; Shah, Alpesh; Stow, Jessie; Walton, Hugh; Wilsher, Nicola

Martins, Vanessa; Fazal, Lynsey; Oganesian, Aram; Shah, Alpesh; Stow, Jessie; Walton, Hugh; Wilsher, Nicola.

Afiliação

Martins V; Astex Pharmaceuticals, Cambridge, UK.
Fazal L; Astex Pharmaceuticals, Cambridge, UK.
Oganesian A; Astex Pharmaceuticals, Pleasanton, CA, USA.
Shah A; Astex Pharmaceuticals, Cambridge, UK.
Stow J; Astex Pharmaceuticals, Cambridge, UK.
Walton H; Astex Pharmaceuticals, Cambridge, UK.
Wilsher N; Astex Pharmaceuticals, Cambridge, UK.

Xenobiotica ; 52(8): 786-796, 2022 Aug.

Article em En | MEDLINE | ID: mdl-36537234

Assuntos

COVID-19; Descoberta de Drogas; Ritonavir; Humanos; Indústria Farmacêutica; Miotonina Proteína Quinase

Palavras-chave

ADMET; P-glycoprotein inhibition; CYP inhibition; Pharmacoenhancer; pharmacokinetics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ritonavir / Descoberta de Drogas / COVID-19 Limite: Humans Idioma: En Revista: Xenobiotica Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google